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Abstract
Enhanced mental and physical activity can have positive effects on the function of aging brain, both in the experimental 
animals and human patients, although cellular mechanisms underlying these effects are currently unclear. There is a grow-
ing evidence that pre-clinical stage of many neurodegenerative diseases involves changes in interactions between astrocytes 
and neurons. Conversely, astrocytes are strategically positioned to mediate the positive influence of physical activity and 
diet on neuronal function. Thus, development of therapeutic agents which could improve the astroglia-neuron communica-
tions in ageing brain is of crucial importance. Recent advances in studies of cellular mechanisms of brain longevity suggest 
that astrocyte-neuron communications have a vital role in the beneficial effects of caloric restriction, physical exercise and 
their pharmacological mimetics on synaptic homeostasis and cognitive function. In particular, our recent data indicate that 
noradrenaline uptake inhibitor atomoxetine can enhance astrocytic  Ca2+-signaling and astroglia-driven modulation of syn-
aptic plasticity. Similar effects were exhibited by caloric restriction-mimetics metformin and resveratrol. The emerged data 
also suggest that astrocytes could be involved in the modulatory action of caloric restriction and its mimetics on neuronal 
autophagy. Still, the efficiency of astrocyte-targeting compounds in preventing age-related cognitive decline is yet to be fully 
explored, in particular in the animal models of neurodegenerative diseases and autophagy impairment.
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Introduction
Due to changing demographics, age-related cognitive 
decline and neurological disorders have become a real medi-
cal and societal problem. Maintaining of cognitive function 
during ageing as well as adaptation of brain to environ-
mental, metabolic and immunological challenges relies on 
synaptic plasticity-an active, continuous process occurring 
throughout the lifespan [1–4]. Remarkable responsiveness 
of brain cellular networks and synapses to environmental 
enrichment, physical activity and changes in the diet can 
help to alleviate the negative impact of ageing on cognitive 
function [2, 4–6]. Recent data [5, 7] show that environmental 
enrichment (EE) and caloric restriction (CR) can ameliorate 
the aging-related alterations in synaptic transmission and 
mitigate the age-related decline in synaptic plasticity in the 
neocortical neurons.
A growing evidence of beneficial effects of exercise and 
diet on brain function gave rise to a concept of “cognitive 
reserve”-a set of cellular and molecular mechanisms which 
allow the brain to adapt to age-related pathologies despite 
underlying neural changes [8]. This concept is particularly 
attractive in view of necessity to develop pharmaceutical 
agents for prevention/amelioration of cognitive decline [3, 
8–11]. Since many elderly, apparently healthy, individu-
als cannot endure prolonged diets or vigorous exercise due 
to pre-diabetes or other symptoms of imminent disease, 
usage of pharmacological agents which mimic the benefi-
cial effects of exercise and CR without provoking their dis-
comfort is attracting an increasing interest [2, 3, 8, 9, 12, 
13]. Progress in the development of such pharmaceuticals, 
Special Issue In Honor of Prof. Vladimir Parpura.
 * Yuriy Pankratov 
 Y.Pankratov@warwick.ac.uk
1 School of Life Sciences, Immanuel Kant Baltic Federal 
University, Kaliningrad, Russia
2 School of Life Sciences, University of Warwick, Coventry, 
UK
2747Neurochemical Research (2021) 46:2746–2759 
1 3
commonly referred as “exercise-mimetics“ or “CR-mimet-
ics”, is hampered by the gaps in our understanding of cel-
lular mechanisms of brain longevity and cognitive reserve. 
Numerous recent studies suggest that neuro-centric view on 
brain aging and neurodegenerative diseases is not compat-
ible with clinical observations, so it becomes evident that 
brain pathologies can be fully understood only in the context 
of the complex cellular networks responsible for the brain 
homeostasis, i.e., astrocyte-neuron, astrocyte-microglia and 
neurovascular units [14–18].
In this article we overview the emerging evidence of 
importance for astrocytes in the mechanisms of cognitive 
reserve which render astroglia a perspective target for CR- 
and exercise mimetics.
Role for Astroglia in the Mechanisms 
of Cognitive Reserve
The results of studies carried out over the last three decades 
show that astrocyte have an active role not only in the meta-
bolic support of neurons but also in the signal processing in 
the neural networks [14, 18–20]. Although electrical signal-
ling is quintessential for the brain function, neurons work-
ing alone seem to provide only a partial explanation for the 
mechanisms of brain plasticity, homeostasis and longevity 
[14, 16–18]. Numerous studies demonstrated that astrocytes 
are chemically excitable and express a plethora of receptors, 
in particular to glutamate, noradrenaline, ATP and endocan-
nabinoids [5, 7, 21–23]. These receptors enable astroglia 
to respond to transmitters spilled out of nearby synapses 
with an elevation of the cytosolic  Ca2+-level [19–24]. In 
return, astrocytes respond to the neurons by releasing small 
molecule transmitters, such as ATP, glutamate and BDNF, 
which modulate synaptic transmission and plasticity [5, 14, 
19, 25–28]. Hence, being in bi-directional communication 
with neurons, astrocytes can indeed play an active roles in 
storage and processing of information in the brain[14, 20]. 
Also, astrocytes mediate metabolic coupling between brain 
vasculature and neurons [20, 29] and thereby are ideally 
placed to couple effects of physical activity and diet to the 
wellbeing of neurons.
Recent research highlighted the need for greater mecha-
nistic understanding of neuron-glia interactions in aging 
and late-life diseases[15, 16, 18, 30, 31]. There is accumu-
lating evidence that functional changes in glia can precede 
molecular and functions changes in neurons and neurode-
generation[16, 17, 31, 32]. Astrocytes are plastic and can 
undergo complex morphological, molecular and functional 
alterations during physiological ageing and in neurodegen-
erative diseases; these alterations range from the loss of 
functions (atrophy) to reactive astrogliosis (hypertrophy) [5, 
7, 17, 31, 33–35]. In particular,  Ca2+ signalling and release 
of gliotransmitters from neocortical astrocytes can undergo 
significant age-related decline [6, 7, 33]. On another hand, 
astrocytic functions and astroglia-neuron interactions can 
enhanced by physical activity, environmental enrichment 
and changes in a diet [5–7, 17, 36, 37]. In particular, the EE 
and CR were reported to increase the astrocytic  Ca2+ signal-
ling and release of gliotransmitters in the neocortex of aged 
mice, which was accompanied by alterations in synaptic 
transmission and plasticity [5, 7, 28]. Furthermore, our data 
demonstrate that EE- and CR-induced enhancement of syn-
aptic plasticity and memory are inhibited in the dnSNARE 
transgenic mice[5, 7, 34] with impaired exocytosis of gli-
otransmitters suggesting an important role for astrocytes in 
cognitive benefits of EE and CR.
Thus, astroglia and efficient astrocyte-neuron interactions 
are crucial component of brain’s cognitive reserve. The age-
related impairment of capability of astrocytes to receive and 
integrate signals from neurons may compromise astroglial 
modulation of synaptic transmission and therefore lead to a 
decline in cognitive function. Conversely, an active lifestyle 
and caloric restriction can enhance astrocytic regulation of 
neuronal function and thereby prevent or even cure the age-
related cognitive impairment. Yet, it remains to be deter-
mined how pharmacological manipulation of astrocytes can 
prevent specific neurological disease initiation or ameliorate 
progression of cognitive decline.
Astroglial Adrenergic Glial Signalling 
as Potential Target of Exercise‐Mimetics
An active lifestyle and physical exercise in particular are 
commonly believed to benefit both physical and mental 
health [2, 4]. Indeed, numerous studies reported beneficial 
effects of active lifestyle and its proxy in animal experiments 
– environmental enrichment - on function of aging brain, 
both in human patients and rodent models [4, 10–12]. It has 
been shown that physical exercise (PE) and environmen-
tal enrichment (EE), which in rodent experiments conven-
tionally includes ad libitum exercise, can reverse atrophic 
changes in neurons [1, 2] and avert the decline in the synap-
tic plasticity and memory associated with aging and neuro-
degenerative diseases [4, 5, 7, 10–12]. However, exercise as 
therapeutic intervention is not easily applicable for diseased 
or elderly patients, especially in current conditions of self-
isolation during pandemic diseases. Thus, development of 
exogenous pharmacological agents capable to activate cel-
lular targets of exercise and reproduce its cognitive benefits 
(“exercise-mimetics”) is viewed as a vital task [2, 38, 39].
The majority of recent studies of potential exercise-
mimetics have been focused mainly on metabolic factors 
activated in skeletal muscles during exercise, such as 5’ 
adenosine monophosphate-activated protein kinase (AMPK) 
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and peroxisome proliferator-activated receptor δ (PPARδ) 
which have been reported to have some beneficial cogni-
tive effects [40, 41]. It was suggested that effects of these 
factors are mediated by molecular cascades involving the 
sirtuins (e.g. SIRT1) and PPARδ coactivator 1α (PGC-1α) 
[12, 40, 41], so the activator of AMPK, AICAR and exog-
enous agonist of PPARδ, GW501516, have emerged as per-
spective exercise-mimetics [38, 40]. One should note that 
majority of molecular interactions of AMPK, SIRT1 and 
PGC-1α have been linked to the caloric restriction modu-
lation of autophagy[9, 42] (discussed below); the specific 
effects of these proteins in astrocytes are not well-studied. 
Most importantly, the efficiency of AICAR and GW501516 
in human patients, even in reproducing cardiovascular ben-
efits of PE, has been put under scrutiny [39, 43] so candidate 
substances to reproduce cognitive benefits of exercise should 
be sought elsewhere.
The noradrenergic neuromodulatory system has recently 
emerged as an important component of cognitive reserve 
[8, 44, 45]. In particular, increase in the brain noradrena-
line (NA) concentration during physical exercise and mental 
activity have been shown to mitigate the negative impact of 
aging and neurodegeneration on synaptic plasticity, memory 
and cognitive flexibility [44–46]. Clinical studies on usage 
of adrenoreceptor agonists and noradrenaline (NA) uptake 
inhibitors for treatment of age- and AD-related depression 
are gaining momentum [8, 44, 47, 48]. Many of NA uptake 
inhibitors permeate the brain-blood barrier, are orally-active 
and have attracted a significant attention as “cognitive 
enhancers”[47, 48].
Interestingly, the release of noradrenaline in the brain 
cortex occurs via “volume transmission”, i.e. from vari-
cosities of adrenergic neurons into brain extracellular fluid, 
rather than into a cleft of specialized synapses [44, 48]. 
Hence, astrocytes can be the first cells to respond to the 
diffuse NA-mediated signals and transmit the information 
to neurons. Indeed, adrenergic signaling has been reported 
to modulate the activity of astrocyte networks according to 
the behavioral state or sensory inputs [14, 15]. Astrocytes 
abundantly express adrenergic α1-receptors [44, 49] which 
have been demonstrated to activate  Ca2+-dependent release 
of gliotransmitters and mediate astroglia-driven modulation 
of synaptic plasticity [5, 22, 50]. Furthermore, adrenergic 
signalling in astrocytes can increase during physical activity 
or after environmental enrichment [5, 36, 49]. So, astroglial 
adrenoreceptors, in particular α1-ARs, represent an impor-
tant part of a “cognitive reserve” and perspective target for 
adrenergic modulators.
It is conceivable that pharmacological modulation of 
noradrenergic signalling by the NA re-uptake inhibitors 
could recapitulate effects of physical exercise on glia-neu-
ron communication, synaptic transmission and cognitive 
functions. In line with this notion, our recent experiments 
showed that long-term incubation of hippocampal slices 
of old mice with small concentrations of atomoxetine (200 
nM) enhanced the astrocytic  Ca2+-signalling (Fig. 1a, b) and 
significantly increased the magnitude of long-term synaptic 
potentiation (LTP) in the CA1 area, thereby recapitulating 
the beneficial effects of EE (Fig. 1c, d). Atomoxetine (ATX) 
has much higher affinity to the NET/SLC6A2 noradrenaline 
transporters and, in the concentration used in our experi-
ments, does not affect uptake of dopamine or serotonin via 
DAT and SERT transporters [51]. Since SLC6A2 transport-
ers located both in astrocytes and adrenergic neurons, one 
could expect efficient inhibition of both glial uptake and 
neuronal re-uptake of noradrenaline [29, 48].
Importantly, neither ATX nor EE were able to enhance 
the LTP in the old dnSNARE mice (Fig. 1c, d) strongly sug-
gesting the key role of astroglial exocytosis in these effects. 
These observations closely agree with our previous results 
obtained in the neocortex [5, 22, 36, 49, 50, 52], which dem-
onstrated that enhancement of astroglial adrenergic signal-
ling and, consequently, release of ATP and D-Serine from 
astrocytes can counter-balance the age-related alterations 
in synaptic transmission and plasticity. Interestingly, ATX 
increased not only the astrocytic  Ca2+-transients evoked by 
noradrenaline, but also the transients evoked by endocan-
nabinoid receptor agonist anandamide (AEA) and  Ca2+ 
responses to the synaptic stimulation (Fig. 1b). The latter 
effects might be explained by the interaction of astroglial 
adrenoreceptors with other G-protein coupled receptors [53], 
in particular trough regulation of their membrane trafficking 
via beta-arrestins [54, 55]. One have to emphasize that con-
centration of ATX used in our experiments was very small 
and could be achieved during daily oral administrations at 
0.1–0.15 mg/kg.b.w. dosage, which is a several times than 
recommended dosage for human patients [56, 57].
These results highlight atomoxetine and, possibly, other 
selective NA re-uptake inhibitors as perspective exercise-
mimetics whose beneficial effects in the ageing brain can, 
most likely, be mediated via enhancement of gliotransmis-
sion and astroglia-neuron interactions.
Role of Autophagy in the Cognitive Effects of Caloric 
Restriction
Apart from physical exercise, caloric restriction (CR) usu-
ally defined as a reduced intake of calories not causing 
malnutrition, is widely suggested as an efficient strategy to 
improve health- and lifespan in most living organisms [9, 
12, 13, 58]. Over the years, numerous studies have reported 
that CR can exert a variety of life-extending effects and 
counteract various age-associated biochemical alterations 
both in the experimental models and human patients [2, 9, 
12, 13, 42, 58]. In mammals, including primates, CR was 
shown to have beneficial effects on longevity and promote 
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an increased healthspan-the period of life during which an 
individual is health-by reducing the incidence of metabolic 
diseases, generally cancer, arteriosclerosis and neurodegen-
eration[12, 59].
Although a variety of beneficial effects of CR on brain 
health and cognitive healthspan have been reported so 
far [12, 59–61], they have been associated mainly with 
improvement of brain health via various metabolic and 
Fig. 1  Effect of atomoxetine on the astroglial  Ca2+ signaling and 
synaptic plasticity in the hippocampus. a, b  Ca2+-signalling was 
evaluated in the astrocytes of CA1 area of hippocampal slices, as 
described previously [5, 22, 25]. The 2–5 month-old (young) and 
14–18 month-old mice (old) were kept either under standard hous-
ing conditions (SH) or exposed to the enriched environment (EE). 
Some hippocampal slices of SH mice were incubated with 200 nM 
NA-uptake inhibitor atomoxetine for 2 hrs followed by 30 min wash-
out prior to recordings (ATX). a Representative multi-photon images 
of astrocytes of old mice pre-loaded with  Ca2+-probe OregonGreen 
BAPTA-2 AM and stained with fluorescent astroglial marker SR101 
and presudo-color images of OGB-2 fluorescence recorded before 
and after application of noradrenaline (NA, 1 µM). Graphs below 
show the time course of OGB-2 fluorescence averaged over regions 
indicated in the fluorescent images before and application of NA and 
after the 100 ms-long episode of 100 Hz high-frequency stimulation 
(HFS) of Schaffer collaterals. b The pooled data (mean ± SD for the 
number of cells indicated) on the peak amplitude and frequency of 
the baseline spontaneous  Ca2+-transients and the net responses to 
the HFS, NA and endocannabinoid receptors agonist AEA (500 nM) 
evaluated in the astrocytes of different age and treatment groups as 
described in [5, 28]. Asterisks (*, **) indicate statistical significance 
(unpaired t-test) of the effect of age, EE- and atomoxetine-treatment. 
Note the significant decrease in the spontaneous and evoked astro-
glial  Ca2+-signalling and increase induced by EE and atomoxetine. 
Note the significant decrease in the spontaneous and evoked astroglial 
 Ca2+-signalling and increase induced by EE and atomoxetine. c, d 
Long-term potentiation (LTP) of the field EPSPs recorded in the hip-
pocampal CA1 area (stratum radiatum) of wild-type and dnSNARE 
mice with impaired gliotransmission [5, 25]. c The time course of 
changes in the fEPSP induced by 1 s-long HFS delivered at zero time, 
measured in the WT and dnSNARE mice of the same age and treat-
ment groups as in (a, b). Dots in the graphs represent the average of 
6 consecutive fEPSPs; data are shown as mean ± SD for number of 
experiments indicated in the panel (D). Data were normalized to the 
fEPSP slope averaged over 10 min period prior to the HFS. d The 
pooled data on the magnitude of LTP ( mean ± SD) evaluated as rela-
tive increase in the fEPSP slope at 60th min, averaged across 10 min 
time window. Note the significant decrease in the LTP magnitude in 
old mice and significant effects of EE and atomoxetine in the wild-
type but not the dnSNARE mice
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neuroendocrine [9, 12, 59] pathways. However, our recent 
work have demonstrated that CR can exert more subtle 
effects on synaptic transmission, plasticity and glia-neuron 
communications [5, 7]. We found that CR can alleviate age-
related alterations in the synaptic transmission, in particular 
up-regulating the glutamatergic synaptic currents and down-
regulating GABAergic inhibition in the neocortical pyrami-
dal neurons [7, 28]. As a result, CR was able to rescue the 
long-term synaptic plasticity in neocortical neurons of old 
wild-type mice [5, 7]. Most likely, these beneficial effects 
are mediated by astrocytes because (1) CR enhanced astro-
glial  Ca2+ signalling and release of gliotransmitters such as 
ATP and D-Serine [5, 28]; (2) beneficial effects of CR were 
strongly attenuated in the dnSNARE mice with selective 
impairment of astroglial exocytosis [5, 28]. These results 
suggest that astroglia can serve as a key cellular mediator of 
benefits of caloric restriction on cognitive functions.
It is widely suggested that life-extending effects and 
health benefits of caloric restriction originate mainly from 
the enhancement of autophagy [12, 62–64]. Macroautophagy 
(hereafter autophagy) is a cellular mechanism by which 
aggregated/misfolded proteins and damaged organelles are 
engulfed within double-membrane vesicles (autophago-
somes) and then, after several stages of vesicular fusion and 
maturation, delivered to lysosomes for degradation [40]. 
Initiation of autophagy in mammalian cells occurs via the 
activity of the Beclin1—vacuolar sorting protein 34 com-
plex (Beclin1-VPS34 complex) [42, 58, 65–67]. Upstream of 
Beclin1-VPS34 complex, initiation of autophagy is regulated 
by a range of different molecular pathways including highly 
conserved nutrient and energy sensors mTOR (mechanistic 
target of rapamycin) and AMP- activated kinase (AMPK). 
Autophagy can also be modulated in a bi-directional man-
ner by lysine acetyltransferases (e.g.EP300) or deacetylases 
(e.g., sirtuins) which correspondingly inhibit or promote 
autophagy [13, 42, 62]. As a catabolic process, autophagy 
is very sensitive to the decrease in nutrients level so it could 
be readily activated by CR and fasting regimens. Indeed, 
CR was widely reported to modulate several key regulatory 
cascades of autophagy [9, 13, 60]. For instance, can CR acti-
vate AMPK, which serves as an energy sensor that inhibits 
the mTOR kinase activity (autophagy suppressor), thereby 
leading to autophagy induction. Also, CR can directly and 
indirectly activate sirtuins (SIRTs) causing protein deacety-
lation and enhancement of autophagy. SIRT1 and AMPK 
may engage in a positive feedforward loop thereby amplify-
ing the response to CR [9, 13]. In a practical sense, CR has 
become a “method of choice” to induce autophagy in differ-
ent types of experimental animals [9, 58].
Although molecular mechanisms underlying the role 
of autophagy in health and disease are not clear yet, ben-
eficial effects of autophagy are commonly attributed to the 
digestion of potentially harmful intracellular structures, like 
aggregates of misfolded dysfunctional proteins and damaged 
organelles [9, 42, 66]. The cytoprotective and life-extending 
effects of autophagy have been observed in various experi-
mental models, including human patients [9, 42, 62]. The 
capacity of a cell to autophagic degradation declines with 
age [13, 63, 66, 68] and alterations of autophagy have been 
implicated in many ageing-related pathological processes, 
including various neurodegenerative diseases [42, 63, 66]. 
On the another hand, chemical or genetic enhancement 
of autophagy has been reported to ameliorate signs of the 
neurodegenerative diseases in various animal models [58]. 
Recent data highlighted the importance of neuronal and 
glial autophagy for synaptic homeostasis and plasticity 
[66, 68–71]. In contrast to the recent advances in the study 
of roles for neuronal and microglial autophagy in neuro-
degeneration, relatively little is known about the specific 
mechanisms and (patho)physiological roles of autophagy in 
astrocytes. Since autophagy is an evolutionarily conserved 
process essential for cell vitality, there are strong grounds to 
believe that regulation of autophagy in astrocytes is medi-
ated by similar molecular cascades as neuronal autophagy 
[72, 73]. Indeed, astrocytes have been reported to express a 
variety autophagy-related proteins and changes in expression 
of these proteins, in particular LC3, P62, Atg5, Atg7 and 
ULK2 have been linked to astroglial response to nutritional 
and oxidative stress and neuroinflammation [72, 73]. There 
is also emerging evidence of astroglia-specific changes in 
autophagy under certain pathological conditions [74, 75]. 
In particular, it has been reported that autophagy in astro-
cytes can be activated much strongly, as compared to neu-
rons, by the metabolic stress and pharmacological inhibition 
of MTOR [74]. Still, role for cell type-specific changes in 
autophagy in brain aging and neurodegeneration is yet to be 
established.
One of the major challenges in the therapeutic applica-
tions of various CR protocols in human patients, like daily 
reduction in food intake or intermittent fasting, is that rela-
tively long-term CR is required to produce beneficial effects 
on healthspan and lifespan, which undermines applicability 
of such interventions [13, 60]. Thus, development of phar-
macological CR-mimetics which could induce the benefi-
cial effects of CR without provoking diet-related discomfort 
attracts a great interest. It is no wonder that most perspec-
tive CR-mimetics have being sought among modulators of 
autophagy [9, 13, 64].
Autophagy Modulators as CR‑Mimetics
One of “oldest” classes of CR-mimetics is rapalogs rep-
resented by mTOR inhibitor rapamycin (sirolimus) and its 
analogs, such as temsirolimus and everolimus. Due to the 
presence of multiple molecular targets of mTOR, rapalogs 
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were reported to have a variety effects on cellular metabo-
lism and senescence majority of which converge to suppres-
sion of gene transcription and protein synthesis and induc-
tion of autophagy and, consequently, reduction of protein 
aggregation[9, 60, 64, 76]. This anti-aggregation action of 
rapalogs, most likely, explains their neuroprotective effects 
reported in several models of [9, 60, 76, 77] neurodegen-
erative diseases. Since life-extending properties of rapalogs 
have been reported in numerous studies from yeast to mam-
mals, series of clinical trials for specific clinical applica-
tions have been conducted or registered for some of these 
drugs but the obtained results, especially on health- and/or 
lifespan-extending effects, were not entirely conclusive [9, 
63, 76]. Furthermore, recently emerged data suggest that 
inhibition of mTOR by rapamycin can also cause negative 
effects on astroglia functions. For instance, inhibition of 
mTORC1 has been reported to activate astrogliosis [78], 
impair the development of the dentate gyrus by depleting 
the astroglia and microglial cellular pools [79] and inhibit 
release of purine gliotransmitters from spinal cord astro-
cytes [80]. These results cast some doubts upon usefulness 
of rapalogs as “enhancers” of astroglia-neuron interactions 
in ageing brain.
Another relatively well-studied CR-mimetic is metformin 
(dimethylbiguanide hydrochloride) which was extensively 
used as anti-diabetic drug [81]. Various metabolism-related 
anti-aging effects of metformin were observed in animal 
models and human patients, mostly in the context of age-
related and neurodegenerative diseases where diabetes is a 
confounding factor [9, 81]. In particular, metformin has been 
reported to improve spatial and recognition memory in the 
aged rodents [82, 83] and regulate gene expression specifi-
cally in reactive astrocytes in the mouse model of Parkin-
son’s disease [84]. The beneficial effects of metformin have 
been attributed to the several molecular cascades, mainly to 
the inhibition of the mitochondrial electron transport chain 
complex I and activation of AMPK, inhibition of mTORC1 
independently of AMPK and direct regulation of SIRT1 
[9, 81]. Apart from regulation of autophagy, metformin 
can have pleiotropic anti-aging effects, the most important 
of which two in the context of present review is improve-
ment of mitochondria function via modulation of oxidative 
phosphorylation and relieving the oxidative stress [9, 81]. 
Since mitochondrial play important role in the regulation 
of cellular  Ca2+-homeostasis, one might expect a benefi-
cial effects of metformin on  Ca2+-signalling in astrocytes. 
Indeed, we observed that incubation of neocortical slices of 
the old mice with 5 µM metformin increased the mitochon-
drial potential and enhanced adrenergic  Ca2+-signalling in 
astrocytes (Fig. 2), thus ameliorating age-related decline in 
astroglial function. Taking into account the positive effect 
of metformin on  Ca2+-dynamics in astrocytes one might 
suggest to combine it with adrenergic EE-mimetics, such 
as atomoxetine. As added benefit of such combination, 
metformin could alleviate the most plausible side-effect of 
NA-uptake inhibitors – hypertension. The anti-hypertensive 
action of metformin is rather well-documented, it relies on 
the ability of metformin to promote mitochondrial biogen-
esis in vascular endothelial cells and activate the endothelial 
NO synthase and NO-dependent vasodilation via AMPK-
dependent pathway [81].
Third group of perspective CR-mimetics are polyphenols 
abundant in the skin of grapes and in the red wine, in par-
ticular resveratrol [13, 60, 85]. Resveratrol has been shown 
to promote longevity across species, in particular amelio-
rate the age-related changes in metabolic and physiological 
parameters and extend life-span of mice on a high-fat diet. 
Also, resveratrol induces a CR-like transcriptional signature 
in mice and recapitulates metabolic metabolic changes of 
CR in humans [9, 68, 85]. Similarly to metformin, resvera-
trol targets a number of stress-related cellular components, 
including the AMPK and SIRT1 which in turn can regulate 
autophagy [9, 68, 85]. Moreover, the resveratrol-induced 
increase in lifespan was abolished following knockdown 
of essential autophagy genes, such as Beclin1 [9, 68]. As 
perspective autophagy modulator, resveratrol is gaining 
increasing interest as potential drug for treatment of neu-
rodegenerative disorders [44, 63, 86]. Still, the molecular 
and cellular mechanisms underlying plausible anti-aging 
effects of resveratrol on the function of aging brain remain 
elusive. Although the health-promoting and life-extending 
effects of resveratrol are presumed to be mediated by modu-
lation of autophagy [9, 85], resveratrol has been shown to 
produce significant effects on AMPK and mTOR only when 
applied in super-pharmacological concentrations (> 20 µM)
[87, 88]. In this regard, our preliminary data demonstrating 
that moderate concentrations (10 µM in situ) of resveratrol 
can enhance the spontaneous and evoked and astrocytic 
 Ca2+-signalling and synaptic plasticity (Fig. 3) attract a 
particular interest. The effect of resveratrol on the synaptic 
plasticity was partially reduced by the autophagy inhibitor 
SAR405 (Fig. 3d) and was precluded in the dnSNARE mice 
with impaired astroglial exocytosis. Hence, one could sug-
gest that resveratrol in moderate doses acts via enhancement 
of astroglial  Ca2+-signalling and glia-neuron interactions 
which might involve regulation of neuronal autophagy.
Recently, a naturally occurring polyamine spermidine has 
emerged as promising anti-aging agent [13, 60, 89]. Spermi-
dine can readily interact with negatively charged molecules, 
including DNA, RNA and lipids, thereby affecting basic cel-
lular functions such as DNA stability, as well as cell growth, 
proliferation and, importantly, autophagy [62]. Spermidine 
can cause both a rapid induction and sustained enhance-
ment of autophagy, correspondingly through the inhibition 
of the acetyl transferase EP300, resulting in deacetylation 
of autophagy-relevant cytosolic proteins, and inhibition 
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of histone acetyl transferases, leading to the induction of 
autophagy-relevant gene transcription [13, 62]. Spermidine 
can be obtained from food or synthesized in mammalian 
tissues so it can serve as a endogenous and exogenous modu-
lator of autophagy. Due to this dual role, health-promoting 
and life-extending effects of spermidine attracted a great 
interest both in the fundamental and clinical studies [9, 62]. 
The blood concentration of spermidine has been reported to 
undergo age-related decrease and inversely correlate with 
severity of symptoms of age-related diseases and mortality 
rate [13, 62, 63, 69].
So far, majority of the data on beneficial effects of sper-
midine on synaptic plasticity has been obtained in flies [62, 
66, 69] and mechanisms of its action on mammalian brain 
cells are not well-established. Our experiments in the neo-
cortical neurons of aged mice (Fig. 4) show that spermidine 
Fig. 2  Impact of metformin on the mitochondrial potential and  Ca2+−
signalling in neocortical astrocytes. a Mitochondrial potential was 
evaluated with the aid of mitochondria-specific potential-sensitive 
ratiometric dye JC1 (Molecular Probes). The ratio of red to green flu-
orescence of JC-1 is dependent only on the mitochondrial membrane 
potential and decreases with mitochondrial depolarization. Neocorti-
cal slices were preloaded with 2 µM of JC-1 for 40 min and green 
(540 ± 15 nm) and red (630 ± 35 nm) fluorescence was measured 
before and after 20 min after application of 5 µM metformin using 
Zeiss LSM-7 2-photon microscope (excitation at 810 nM). Astro-
cytes were initially identified by their morphology under gradient-
contrast illumination, their identification was confirmed at the end of 
recordings by electrophysiological characterization [25]. The upper 
images show superposition of the gradient-contrast image of astro-
cytes with red and green JC-1 fluorescence in the control and after 
incubation with metformin, the lower pseudo-color images show cor-
responding ratio of red to green signal. The diagram shows pooled 
data (mean ± SD for 30 cells) on the JC-1 fluorescence recorded in 
astrocytes from young (3–6 months) and old (14–18) mice. Note the 
age-related decrease in the red/green ratio, indicative for mitochon-
drial depolarization, in the old mice and metformin-induced increase 
in the mitochondrial potential. b, c 2-photon fluorescent images 
(pseudo color) and  Ca2+-signals were recorded in the neocortical 
astrocytes of 14 months- old mice loaded with  Ca2+-indicator OGB-
2AM, as described previously [5, 22, 25], before (control) and 20 min 
after application of 5 µM metformin. c The pooled data on the ampli-
tude of spontaneous  Ca2+ and net response to 1µM noradrenaline 
(NA, 1 µM) and CB1 receptor agonist anandamide (AEA, 500 nM). 
Note the significant increase both in the spontaneous and evoked 
 Ca2+-signalling after the application of metformin.
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Fig. 3  Effects of resveratrol on astroglial  Ca2+ signalling and syn-
aptic plasticity in neocortex of old mice. a, b  Ca2+-signalling was 
evaluated in the astrocytes of layer 2/3 of somatosensory cortex of 
12–16 months old wild-type mice as described in [5, 22, 23]. Astro-
cytic  Ca2+-transients were activated by agonists of CB1 receptors 
(AEA 500 nM) and adrenoreceptors (NA, 1 µM) in control and after 
1 h-long pre-incubation with resveratrol (20 µM). a Representative 
2-photon recordings of OGB-2 fluorescence in the neocortical astro-
cytes of 13 months-old wild-type mouse. b Pooled data for n = 10 
astrocytes from 12 to 16 old mice. c, d The long-term potentiation 
of the field EPSPs in the neocortical layer 2/3 of 12–16 months old 
wild-type and dnSNARE mice. The LTP was induced by 50 pulses of 
theta-burst stimulation (as described in [5]) in the control and after 1 
h pre-incubation of slices with resveratrol alone or resveratrol in com-
bination with autophagy inhibitor SAR405 (200 nM). d Pooled data 
on the magnitude of LTP at 60 min, the data are shown as mean ± SD 
for the number of experiments indicated in (c). The beneficial effect 
of resveratrol is significantly reduced in the dn-SNARE mice with 
impaired exocytosis of gliotransmitters from astrocytes and is antago-
nized by selective inhibitor of autophagy SAR405
Fig. 4  Spermidine down-regulates GABAergic inhibitory currents in 
the neocortical neurons. a The GABAergic currents were evoked in 
the acutely isolated neurons of 3 months-old (young) and 14 month-
old (old) mice by application of 100 µM GABA and measured using 
whole-cell voltage-clamp as described previously [25, 50, 52]. Neu-
rons were acutely dissociated from the hippocampal slices [50, 52] 
incubated either with spermidine (10 µM) alone or with spermidine 
and autophagy inhibitor SAR405 [86] (200 nM), which specifically 
inhibits vacuolar sorting protein VSP34. b Pooled data on the density 
of GABA-induced currents under different conditions (mean ± SD 
for 5 cells). Note that spermidine causes significant down-regulation 
of GABAergic currents which is blocked by SAR405, suggesting an 
involvement of autophagic mechanisms
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can up-regulate neuronal autophagy and down-regulate 
the GABAergic transmembrane currents in the autophagy-
dependent manner (Fig. 4c). The latter effect of spermidine 
could, potentially, shift the balance between excitation and 
inhibition and thereby facilitate the induction of long-term 
synaptic plasticity. Still, influence of spermidine on astro-
glial signalling and glia-neuron interaction remain to be 
explored.
Effects of Autophagy Modulation in the Context 
of Synaptic Transmission and Astrocyte–Neuron 
Interactions
Majority of the effects of autophagy on brain function 
reported so far has been linked to retarding neurodegenera-
tion via improvement of neuronal metabolism and proteosta-
sis [12, 42, 66]. Nevertheless, there is growing evidence that 
molecular machinery of autophagy can be directly involved 
in regulation of synaptic transmission and plasticity, affect-
ing the synaptic efficacy both at presynaptic and postsynap-
tic loci [68, 71]. These effects could originate from interac-
tion of autophagy-regulating proteins with mechanisms of 
trafficking of synaptic vesicles and membrane trafficking, 
endocytosis and degradation of neurotransmitter receptors 
and ion channels [67, 68, 71]. One might argue that in ageing 
brain direct impact of autophagy on synaptic dynamics could 
be no less important than the autophagy-mediated neuropro-
tection. Recent data obtained in the model organisms (flies) 
suggest that decline in autophagic capacity of neurons can 
cause synaptic degeneration and cognitive deficits [66, 70]. 
At the same time, enhancement of autophagy by dietary 
spermidine has been reported to ameliorate the age-induced 
memory impairment, most likely via autophagy-dependent 
rejuvenation of synaptic active zones [58, 62].
The specific molecular cascades underlying putative role 
for autophagy in the effects of CR and CR-mimetics on syn-
aptic transmission and cognitive functions remain largely 
unexplored. Whereas numerous studies have reported vari-
ous molecular interactions between autophagy-related pro-
teins and elements of synaptic machinery, predominantly in 
non-mammalian models [42, 66, 68], observations of direct 
effects of modulation of autophagy on synaptic plasticity in 
mammalian brain tissue remain scarce [66, 71].
The less ambiguous is mechanism of autophagy-mediated 
modulation of inhibitory synaptic transmission which, most 
likely, involves the modulation of GABAA receptor traf-
ficking via Beclin1-VSP34-GABARAP cascade [86]. This 
mechanism has recently been implicated in the effects of 
VSP34 inhibitor SAR405 on inhibitory neurotransmission 
in amygdala and fear memory [86]. Our observations of the 
action of SAR405 on synaptic plasticity in neocortex (Fig. 3) 
and down-regulation of GABAergic currents by spermidine 
(Fig. 4) strongly support the notion that autophagy regulates 
inhibitory synaptic transmission via Beclin1-VSP34 cascade.
The impact of autophagy on glutamatergic excitatory 
transmission remains uncertain, especially at the post-syn-
aptic site [66, 71] where, arguably, most important events 
of long-term synaptic plasticity occur. On the one hand, the 
impact of autophagy on recycling endocytosis and lysosomal 
sorting of glutamate receptors has recently been suggested as 
important regulator of strength of excitatory synapses [71, 
90, 91] and on the another hand, different studies attrib-
uted the improvement of synaptic plasticity (in different 
pathological context) both to the decrease and increase in 
autophagy (in the different pathological context) [9, 42, 66, 
68, 71]. Two main molecular pathways has been suggested 
to be responsible for regulation autophagy in excitatory 
synapses: down-regulation of autophagy via regulation of 
mTOR by BDNF and enhancement of autophagy by spermi-
dine acting via protein de-acetylation and FOXO transcrip-
tion factor [9, 66, 71].
Intriguingly, astrocytes can participate in the storage and 
release of the above-mentioned endogenous modulators of 
autophagy. Astrocytes have been reported to release BDNF 
[27] and astroglia-derived BDNF has been implicated in the 
homeostatic scaling of glutamatergic synapses during EE 
[28]. Although the latter effect has been attributed to the 
TrkB receptor-MSK1-Arc pathway [28, 92], the modulation 
of autophagy by astroglia-derived BDNF is still plausible. 
As for the spermidine, astrocytes have high capacity for 
uptake of spermidine form the blood by virtue of express-
ing the organic cation transporters OCT1-3 [93] and its con-
tent in astrocytes was reported to be much higher than in 
neurons [94, 95]. Finally, it has been recently discovered 
that astrocytes can store spermidine in vesicles by virtue 
of abundant expression of vesicular polyamine transporter 
SLC18B1 [96].
Thus, one might speculate that astrocytes can regulate 
neuronal autophagy by releasing BDNF and/or spermi-
dine. However surprising and fanciful this hypothesis 
may seem, it is supported by our pilot data on astroglia-
driven modulation of synaptic transmission and plasticity 
in the neocortical neurons of the Beclin1-deficient mice 
(Fig. 5). As a model of inducible impairment of neuronal 
autophagy, we used the cross between  Camk2aCreERT2/+ 
and  Becn1Fl/Fl [97] lines  (Becn1+/− mice). We evaluated 
the miniature spontaneous inhibitory currents (mIPSCs) 
in the pyramidal neurons and long-term synaptic poten-
tiation of field EPSPs in the neocortical layer 2/4. For 
sustained tonic activation of astrocytes, neocortical slices 
were incubated for 1 hrs with 3 µM of PAR-1 receptor 
agonists TFLLR (followed by 30 min wash-out), this 
approach has been previously demonstrated to activate 
 Ca2+-signalling in selectively in astrocytes and trigger 
the release of gliotransmitters [25, 34, 52]. To avoid a 
2755Neurochemical Research (2021) 46:2746–2759 
1 3
plausible effect of astroglia-derived ATP on the GABAA 
receptors [25], TFLLR was applied in the presence of puri-
noreceptors antagonists PPADS and 5-BDBD. Under con-
trol conditions, the average amplitude and quantal size of 
the GABAergic mIPSCs in the neurons of  Becn1+/− mice 
were significantly larger (Fig. 5a) and the magnitude of 
LTP significantly smaller (Fig. 5c) than in their wild-
type  (Becn1+/+) littermates. Activation of astrocytes 
Fig. 5  Impact of activation of astrocytes on the inhibitory synap-
tic transmission and synaptic plasticity in the neocortical neurons 
of autophagy-deficient mice. The Beclin1-deficient mice (Becn1+/−) 
were obtained by crossing the  Becn1fl/fl and  Camk2acreERT2/+ trans-
genic lines. The 6–8 weeks old mice were kept under standard hous-
ing conditions for 4 weeks after tamoxifen injections. a, b The min-
iature spontaneous inhibitory synaptic currents (mIPSCs) recorded 
in the neocortical layer 2/3 pyramidal neurons of the Becn1+/− mice 
and their wild-type littermates (Becn1+/+). a The representative mIP-
SCs were recorded as described in [25] in the presence of NBQX 
and TTX in the control conditions and after exposure of hippocam-
pal slices to the agonist of astroglia-specific PAR1 receptors TFLLR 
(3 µM). The quantal amplitude and frequency of the mIPSCs were 
quantified as described in [25, 52]. b The diagram shows the pooled 
data (mean ± SD for number of neurons indicated) on the changes 
in quantal amplitude of mIPSCs (indicative for the postsynaptic 
changes) induced by activation of astrocytes with TFLLR. Note the 
increase in the amplitude of baseline mIPSCs and the lack of effect 
of TFLLR in the Becn1+/− mice. c-e The long-term potentiation of 
fEPSPs in the neocortical layer 2/3 of the same mice cohorts as in (a, 
b). The LTP was induced by 30 pulses of theta-burst stimulation (as 
described in [5]) in the control and after pre-incubation of slices with 
TFLLR alone or TFLLR with 200 nM SAR405 c or with 10 µM sper-
midine (d). e Pooled data on the magnitude of LTP in the wild-type 
and Becn1+/− mice (mean ± SD for the number of experiments indi-
cated). Note the impairment of LTP in the Becn1+/− mice and inhibi-
tion of the TFLLR-induced facilitation of LTP by autophagy inhibitor 
SAR405
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with TFLLR considerably decreased the mIPSCs in the 
wild-type but not in the Beclin1-deficient mice (Fig. 5a, 
b). In the wild-type mice, the effect of astrocyte activa-
tion on mIPSCs was reproduced by the preapplication 
with 10 µM of spermidine and decreased by the VSP34 
inhibitor SAR405 (Fig. 5b). In line with the changes in 
the inhibitory synaptic currents, incubation of neocortical 
slices with TFLLR or spermidine enhanced the LTP in the 
neocortex in the VSP-34 and Beclin1-dependent manner 
(Fig. 5c, d). These results may imply that astrocytes can 
release some factors, presumably spermidine, to regulate 
neuronal autophagy at the post-synaptic locus, most likely 
via the Beclin1-VSP34-pathway.
Future Directions
It becomes evident that caloric restriction and its phar-
macological mimetics have a great therapeutic potential 
for treatment age-related brain disorders. Taken together, 
recent data indicate that astroglia can have a pivotal role in 
the beneficial effects of exercise and caloric restriction and 
their pharmacological mimetics on brain health and cogni-
tive longevity. Apart from improvement of metabolism and 
proteostasis in the neuronal and glial cells, exercise- and 
caloric restriction-mimetics can exert more subtle, but not 
less important, effects on synaptic transmission, in which 
astrocyte can take an active role. The most plausible mech-
anism underlying such a role is enhancement of astroglial 
 Ca2+-signalling and release of gliotransmitters which, in 
turn, modulate synaptic dynamics and homeostasis thereby 
alleviating the age-related decline in synaptic plasticity 
and cognitive functions. A good example of such action 
is provided by the perspective exercise-mimetics atomox-
etine, the noradrenaline uptake inhibitor. Its positive effect 
on astroglial signalling might be synergistically enhanced 
by CR-mimetics metformin which can act via improvement 
of mitochondrial function. Still, the suitability of atomox-
etine or atomoxetine/metformin combination for treatment 
of aging-related cognitive decline is yet to be investigated.
A variety of positive effects of many CR-mimetics, 
such as metformin or resveratrol, on synaptic transmis-
sion and plasticity in the aging brain involve regulation 
of autophagy and the most intriguing question here is 
whether astroglia can modulate neuronal autophagy by 
releasing some endogenous modulators, presumably sper-
midine or BDNF. However, the data on impact of CR-
mimetics and autophagy modulators on synaptic function 
and astrocyte-neuron interactions in the aging mammalian 
brain are very scarce and their efficiency in preventing 
age-related cognitive decline is yet to be fully explored, 
in particular in the mammalian animal models of cell-type 
specific impairment of autophagy.
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